Zenith Epigenetics Corp.

Resverlogix Corporation

Laura M Tsujikawa

Christopher Ra Halliday

Dean Gilham

Ewelina B Kulikowski

Dean E Gilham

Sylwia Wasiak

Christopher R A Halliday

Eric Campeau

Sanjay Lakhotia

The invention provides methods for treating triple negative breast cancer (TNBC), by co-administration of a BET bromodomain inhibitor selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof, and a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be a PARP inhibitor, such as, e.g., talazoparib, olaparib or veliparib. 

Combination therapy for the treatment of triple-negative breast cancer

The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.

Compositions and therapeutic methods for the treatment of complement-associated diseases

Growing community of inventors

Calgary, Canada

Laura M Tsujikawa